|
Market Closed -
Nasdaq
20:00:00 13/03/2026 GMT
|
5-day change
|
1st Jan Change
|
|
55.05 USD
|
+0.07%
|
 |
-7.97%
|
-17.08%
|
|
02-24 |
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
|
BU
| |
02-22 |
Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.
|
CI
| |
02-22 |
Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.
|
CI
| |
02-22 |
Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.
|
CI
| |
02-09 |
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 - Biotechnology
|
CI
| |
02-09 |
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care
|
CI
| |
02-09 |
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400
|
CI
| |
02-09 |
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600 Health Care
|
CI
| |
02-09 |
Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) dropped from S&P 600
|
CI
| |
02-06 |
Arrowhead Pharmaceuticals, Inc., Q1 2026 Earnings Call, Feb 05, 2026
| | |
02-05 |
Arrowhead Pharmaceuticals : ARWR FQ1 2026 Script Final
|
PU
| |
02-05 |
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
|
BU
| |
02-05 |
Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M
|
MT
| |
02-05 |
Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M
|
MT
| |
02-05 |
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025
|
CI
| |
02-04 |
Ciena Set to Join S&P500
|
MT
| |
01-27 |
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
|
CI
| |
01-27 |
Arrowhead Pharmaceuticals Doses First Subject in Clinical Trial of Treatment for Mixed Hyperlipidemia
|
MT
| |
01-27 |
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
|
BU
| |
01-22 |
B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating
|
MT
| |
01-20 |
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
|
BU
| |
01-13 |
Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026
|
CI
| |
01-12 |
Arrowhead Pharmaceuticals issues $700 million of 0.00% convertible notes due 2032 - SEC filing
|
RE
| |
01-12 |
Arrowhead Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 07:30 AM
| | |
01-08 |
Arrowhead Pharmaceuticals Prices Offerings of Notes, Common Stock, Pre-Funded Warrants
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
